Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

por Sanchez-Luna, M., Burgos-Pol, R., Oyagüez, I., Figueras-Aloy, J., Sánchez-Solís, M., Martinón-Torres, F., Carbonell-Estrany, X.
Publicado 2017